Stryker announces definitive agreement to acquire Vertos Medical, Inc., expanding interventional pain management solutions
22 Agosto 2024 - 7:00AM
Stryker (NYSE: SYK), a global leader in medical technologies,
announced today a definitive agreement to acquire Vertos Medical
Inc., a privately held company providing a minimally invasive
solution for treating chronic lower back pain caused by lumbar
spinal stenosis.
Lumbar spinal stenosis affects millions of people globally and
is a leading cause of pain and disability. Patients today are
seeking minimally invasive treatment options, valuing reduced
recovery times and quicker returns to daily life. Vertos Medical’s
mild® procedure provides a solution for pain relief and may improve
mobility1,2 without the need for major surgery.
“We are committed to helping customers restore patients’ quality
of life with interventional solutions to address chronic pain,”
said Andy Pierce, Group President, MedSurg and Neurotechnology,
Stryker. “This acquisition strengthens our minimally invasive pain
management portfolio with differentiated treatments and expands our
reach across ambulatory surgery centers.”
“Allowing patients to get back to what matters most to them is
what matters most to us,” said Eric Wichems, Vertos Medical’s Chief
Executive Officer. “Stryker’s mission and focus on interventional
solutions provides an opportunity to further improve patients'
quality of life.”
This transaction is subject to customary closing conditions.
Stryker and Vertos Medical Inc. will continue to operate as
separate entities and proceed with business as usual until the
transaction closes.
About StrykerStryker is a global leader in
medical technologies and, together with its customers, is driven to
make healthcare better. The company offers innovative products and
services in MedSurg, Neurotechnology, Orthopaedics and Spine that
help improve patient and healthcare outcomes. Alongside its
customers around the world, Stryker impacts more than 150 million
patients annually. More information is available at
www.stryker.com.
Media contactBeth SizemoreSr. Director,
Strategic Communicationsbeth.sizemore@stryker.com
References
- Deer TR, Chafin TB, Costandi SJ, Qu H, Kim C, Jassal N, Patel
K, Calodney A. The MOTION study: Two-year results of a real-world
randomized controlled trial of the mild® procedure for treatment of
lumbar spinal stenosis. Pain Pract. 2024 Jan;24(1):109-119.Deer TR,
Costandi SJ, Washabaugh E, Chafin TB, Wahezi SE, Jassal N, Sayed D.
The MOTION Study: A Randomized Controlled Trial with Objective
Real-World Outcomes for Lumbar Spinal Stenosis Patients Treated
with the mild® Procedure: One-Year Results. Pain Med. 2022 Apr
8;23(4):625-634.
Stryker (NYSE:SYK)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Stryker (NYSE:SYK)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024